Lerkanidipin Actavis (Lercanidipine Hydrochloride)

Lercanidipine is a calcium channel blocker used in the management of high‑blood‑pressure conditions.

• Essential hypertension: lowers systolic and diastolic blood pressure, helping to prevent stroke and heart attack.
• Isolated systolic hypertension: reduces elevated systolic pressure, particularly in older adults.
• Hypertension in elderly patients: provides effective blood pressure control with a favorable tolerability profile.

• Lercanidipine hydrochloride selectively blocks L-type calcium channels in vascular smooth muscle, inhibiting calcium influx. This results in relaxation of arterial smooth muscle, leading to vasodilation, decreased peripheral vascular resistance, and ultimately a reduction in systemic blood pressure without significant effect on cardiac conduction.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate pain often occurring after the first dose.
• Flushing: sensation of warmth and redness, typically on the face or neck.
• Peripheral edema: swelling of the ankles or feet due to fluid accumulation.
• Dizziness: light‑headed feeling, especially when standing quickly.
• Fatigue: general tiredness that may improve with continued therapy.
• Tachycardia: increased heart rate, usually mild.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting or shock.
• Myocardial infarction: rare occurrence of heart attack, particularly in patients with existing coronary disease.
• Arrhythmias: abnormal heart rhythms that may require medical attention.
• Hepatic injury: signs of liver dysfunction such as jaundice or elevated enzymes.
• Allergic reactions: rash, itching, swelling, or difficulty breathing indicating possible anaphylaxis.

Before initiating therapy, clinicians should consider several safety aspects.

• Blood pressure monitoring: ensure adequate control and avoid excessive hypotension.
• Hepatic impairment: use caution and consider dose adjustment in patients with liver dysfunction.
• Elderly patients: start at the lowest effective dose and monitor for dizziness or falls.
• Concomitant antihypertensives: assess for additive blood‑pressure‑lowering effects.
• Severe aortic stenosis: contraindicated due to risk of precipitating cardiac failure.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension.
• Grapefruit juice: can markedly raise lercanidipine levels, leading to enhanced adverse effects.
• Other potent antihypertensives: may cause additive blood‑pressure reduction and syncope.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug exposure, diminishing therapeutic effect.

• Diuretics: can potentiate orthostatic hypotension; monitor electrolytes and blood pressure.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate antihypertensive response; assess renal function regularly.